Core Viewpoint - Demais (301007) announced on October 10 that as of September 30, 2025, the number of registered shareholders is approximately 13,400 [1] Summary by Categories - **Company Information** - Demais has approximately 13,400 registered shareholders as of September 30, 2025 [1] - **Investor Communication** - The company responded to investor inquiries on its interactive platform regarding shareholder numbers [1]

Core Viewpoint - Demais (301007.SZ) announced that as of September 30, 2025, the company has not repurchased any shares [1] Summary by Category - Company Actions - Demais has not engaged in any share repurchase activities up to the specified date [1]

证券代码：301007 证券简称：德迈仕 公告编号：2025-041 大连德迈仕精密科技股份有限公司 截至2025年9月30日，公司暂未回购股份。 二、回购公司股份的合法合规性说明 公司回购股份的时间、回购价格及集中竞价交易的委托时间段等均符合公司 回购股份的方案及《深圳证券交易所上市公司自律监管指引第9号——回购股份 》第十七条、第十八条的规定，具体说明如下： （一）公司未在下列期间回购股份： 1、自可能对公司证券及其衍生品种交易价格产生重大影响的重大事项发生 之日或者在决策过程中，至依法披露之日内； 2 、中国证监会和深圳证券交易所规定的其他情形。 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 大连德迈仕精密科技股份有限公司（以下简称"公司"）于2025年4月21日 召开第四届董事会第三次会议和第四届监事会第三次会议，审议通过了《关于 回购公司股份方案的议案》，同意公司使用总额不低于人民币5,000万元（含） 且不超过人民币10, 000万元（含）自有或自筹资金以集中竞价交易的方式回购 公司部分人民币普通股A股股份，用于实施股 ...

Core Insights - The article highlights the significant net inflow of main funds into specific stocks over a period of five days or more, indicating strong investor interest and potential growth opportunities in these companies [1][2] Group 1: Key Stocks with Net Inflows - Cambrian Biologics-U (688256) leads with a continuous net inflow for 30 days, totaling 4.192 billion CNY, with a price increase of 41.87% [1] - Huayou Cobalt (603799) follows with a net inflow of 1.829 billion CNY over five days, reflecting a 25.57% increase [1] - Zhongnan Media (601098) has seen a net inflow for eight days, amounting to 1.111 billion CNY, with a minimal price change of 0.16% [2] Group 2: Notable Inflow Metrics - The highest net inflow percentage relative to trading volume is observed in Hebang Biology (603077), with a 13.89% ratio and a price increase of 8.90% over five days [1] - The total net inflow for Cambrian Biologics-U over 30 days is 4.192 billion CNY, indicating strong market confidence [1] - Other notable stocks include Tianqi Lithium (002466) with a net inflow of 576 million CNY and a price increase of 11.09% [1]

Core Points - Demais Precision Technology Co., Ltd. announced the resignation of CFO Li Jian due to personal reasons, effective immediately upon delivery of the resignation to the board [1] - Li Jian's original term was set from October 28, 2024, to October 27, 2027 [1] - The board approved the appointment of Li Pengyu as the new CFO [1] - For the first half of 2025, Demais's revenue composition was 99.34% from manufacturing and 0.66% from other businesses [1] - As of the report date, Demais's market capitalization was 7.1 billion yuan [1]

Core Viewpoint - Demais announced the election of Mr. Luo Boyang as the employee representative director of the company's fourth board of directors during the employee representative assembly held on September 26, 2025 [2] Group 1 - The employee representative assembly was held on September 26, 2025 [2] - Mr. Luo Boyang was elected as the employee representative director [2] - The election process involved democratic discussion and voting [2]

Core Viewpoint - Demais announced the appointment of Li Pengyu as the new Chief Financial Officer following the approval of the company's fourth board meeting [2] Group 1 - The announcement was made on the evening of September 26 [2] - The decision was made based on the nomination by the company's general manager [2] - The board meeting was the seventh of the fourth session [2]

Core Points - The company Demais (301007) announced the election of Mr. Pan Yi as the chairman of its fourth board of directors [1] Group 1 - The board of directors of Demais has elected a new chairman [1]

Group 1 - The company Demais announced an emergency board meeting on September 26, 2025, to discuss the election of the chairman of the board [1] - For the first half of 2025, the company's revenue composition was 99.34% from manufacturing and 0.66% from other businesses [1] - As of the report, Demais has a market capitalization of 7.1 billion yuan [1] Group 2 - There has been a significant increase in demand for a new type of insurance, with a growth of 33 times over five years, attracting over 30 insurance companies to enter the market [1]

大连德迈仕精密科技股份有限公司 关于公司董事会完成改选暨 选举董事长及专门委员会委员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：301007 证券简称：德迈仕 公告编号：2025-039 大连德迈仕精密科技股份有限公司（以下"公司 "）于2025年9月26日召开 2025年第一次临时股东大会，审议通过了《关于改选公司第四届董事会非独立董 事的议案》《关于改选公司第四届董事会独立董事的议案》。公司于2025年9月26 日召开第四届董事会第七次会议，审议通过了《关于选举公司第四届董事会董事 长的议案》《关于选举公司第四届董事会专门委员会委员的议案》，现将相关情 况公告如下： 一、公司第四届董事会改选后情况 公司第四届董事会由9名董事组成，其中非独立董事5名，独立董事3名，职工 代表董事1名。具体情况如下：非独立董事：潘异先生、何建平先生、祖博女士、 刘国伟先生、陆松泉先生；职工代表董事：骆波阳先生；独立董事：苏勇先生、 耿云江女士、孙小雲女士，上述董事的简历见附件。 二、选举第四届董事会董事长情况 董事会选举潘异先生任公司第四届董事会董事长， ...